SC 13G 1 greatpoint-uncy071624.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. )*



Unicycive Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

90466Y103

(CUSIP Number)

 

 

July 16, 2024
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)

x Rule 13d-1(c)

o Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 
 

CUSIP No.  90466Y103
 SCHEDULE 13G
Page 2 of 9 Pages

 

         
1
NAME OF REPORTING PERSONS
 
Great Point Partners, LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 

8,559,000

7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
8,559,000
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
8,559,000
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
x1
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
9.99%2
12
TYPE OF REPORTING PERSON
 
IA/OO

1 In addition to an aggregate of 8,559,000 shares of the Issuer's common stock (the “Common Stock”) held outright (as a result of the conversion of preferred stock immediately upon effective registration of the Issuer’s S-3), the reporting persons hold in the aggregate preferred stock (the “Preferred Stock”) that may convert into an additional 6,441,000 shares of Common Stock. However, the provisions of such Preferred Stock restrict the conversion of such Preferred Stock to the extent that, after giving effect to such conversion, the holder of the Preferred Stock and its affiliates, together with any other person or entities with which such holder would constitute a group, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion (the “Beneficial Ownership Cap”). As a result, no shares underlying such Preferred Stock are beneficially owned by the reporting persons at this time.

 

2 Based on a total of 85,681,212 shares outstanding as reported by the Issuer in its Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on July 5, 2024.

 
 

CUSIP No.  90466Y103
 SCHEDULE 13G
Page 3 of 9 Pages

 

         
1
NAME OF REPORTING PERSONS
 
Dr. Jeffrey R. Jay, M.D.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
USA
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
8,559,000
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
8,559,000
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
8,559,000
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
x1
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
9.99%2
12
TYPE OF REPORTING PERSON
 
IN/HC

1 In addition to an aggregate of 8,559,000 shares of the Issuer's common stock (the “Common Stock”) held outright (as a result of the conversion of preferred stock immediately upon effective registration of the Issuer’s S-3), the reporting persons hold in the aggregate preferred stock (the “Preferred Stock”) that may convert into an additional 6,441,000 shares of Common Stock. However, the provisions of such Preferred Stock restrict the conversion of such Preferred Stock to the extent that, after giving effect to such conversion, the holder of the Preferred Stock and its affiliates, together with any other person or entities with which such holder would constitute a group, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion (the “Beneficial Ownership Cap”). As a result, no shares underlying such Preferred Stock are beneficially owned by the reporting persons at this time.

 

2 Based on a total of 85,681,212 shares outstanding as reported by the Issuer in its Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on July 5, 2024.

 
 

CUSIP No.  90466Y103
 SCHEDULE 13G
Page 4 of 9 Pages

 

         
1
NAME OF REPORTING PERSONS
 
Mr. Ortav Yehudai
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
USA
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
8,559,000
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
8,559,000
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
8,559,000
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
x1
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
9.99%2
12
TYPE OF REPORTING PERSON
 
IN/HC

1 In addition to an aggregate of 8,559,000 shares of the Issuer's common stock (the “Common Stock”) held outright (as a result of the conversion of preferred stock immediately upon effective registration of the Issuer’s S-3), the reporting persons hold in the aggregate preferred stock (the “Preferred Stock”) that may convert into an additional 6,441,000 shares of Common Stock. However, the provisions of such Preferred Stock restrict the conversion of such Preferred Stock to the extent that, after giving effect to such conversion, the holder of the Preferred Stock and its affiliates, together with any other person or entities with which such holder would constitute a group, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion (the “Beneficial Ownership Cap”). As a result, no shares underlying such Preferred Stock are beneficially owned by the reporting persons at this time.

 

2 Based on a total of 85,681,212 shares outstanding as reported by the Issuer in its Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on July 5, 2024.

 
 

 

CUSIP No. 90466Y103
 SCHEDULE 13G
Page 5 of 9 Pages

 

Item 1.(a) Name of Issuer

Unicycive Therapeutics, Inc.

Item 1.(b) Address of Issuer’s Principal Executive Offices

4300 El Camino Real, Suite 210

Los Altos, CA 94022

 

Item 2.(a) Names of Persons Filing:

Great Point Partners, LLC

Dr. Jeffrey R. Jay, M.D.

Mr. Ortav Yehudai

 

The Reporting Persons have entered into a Joint Filing Agreement, dated July 18, 2024, a copy of which is filed with this SCHEDULE 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

 

Item 2.(b) Address of Principal Business Office:

The address of the principal business office of each of the Reporting Persons is

 

165 Mason Street, 3rd Floor

Greenwich, CT 06830

 

Item 2.(c) Citizenship:

Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. Ortav Yehudai is a citizen of the United States.

  

Item 2.(d) Title of Class of Securities

Common Stock, par value $0.001 per share (the “Common Stock”)

 

Item 2.(e) CUSIP No.:

90466Y103

 

CUSIP No.  90466Y103
 SCHEDULE 13G
Page 6 of 9 Pages

 

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

  (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
 
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
 
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
 
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
 
  (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
 
  (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
 
  (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
 
  (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 
  (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 
  (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
 
  (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
       

 

CUSIP No. 90466Y103
 SCHEDULE 13G
Page 7 of 9 Pages

 

 

Item 4. Ownership

The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover pages for the Reporting Persons and is incorporated herein by reference.

The percentage set forth in Row (11) of the cover pages for the Reporting Persons are based on a total of 85,681,212 shares outstanding, as reported by the Issuer in its Form S-3 filed with the Securities and Exchange Commission (the "SEC") on July 5, 2024.

Biomedical Value Fund, L.P. (“BVF”) is the record holder of 4,725,000 shares of Common Stock (the “BVF Shares”). Such shares constitute 5.51% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. BVF is the record holder of Preferred Stock to convert an additional 3,555,000 shares of Common Stock (the “BVF Preferred”). As a result of the Beneficial Ownership Cap, no shares underlying such Preferred Stock are convertible at this time. Each of Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as Senior Managing Member of Great Point, and Mr. Ortav Yehudai (“Mr. Yehudai”), as Managing Director of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares.

Biomedical Offshore Value Fund, Ltd. (“BOVF”) is the record holder of 3,252,000 shares of Common Stock (the “BOVF Shares”). Such shares constitute 3.80% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. BOVF is the record holder of Preferred Stock to convert an additional 2,448,000 shares of Common Stock (the “BOVF Preferred”). As a result of the Beneficial Ownership Cap, no shares underlying such Preferred Stock are convertible at this time. Each of Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as Senior Managing Member of Great Point, and Mr. Ortav Yehudai (“Mr. Yehudai”), as Managing Director of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares.

Cheyne Global Equity Fund (an Open-Ended Fund of Cheyne Select Master Fund ICAV) (“CGEF”) is the record holder of 582,000 shares of Common Stock (the “CGEF Shares”). Such shares constitute 0.68% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. CGEF is the record holder of warrants to purchase an additional 438,000 shares of Common Stock (the “CGEF Preferred”). As a result of the Beneficial Ownership Cap, no shares underlying such Preferred Stock are convertible at this time. Each of Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as Senior Managing Member of Great Point, and Mr. Ortav Yehudai (“Mr. Yehudai”), as Managing Director of Great Point, has voting and investment power with respect to the CGEF Shares, and therefore may be deemed to be the beneficial owner of the CGEF Shares.

 Notwithstanding the above, Great Point, Dr. Jay and Mr. Yehudai disclaim beneficial ownership of the BVF Shares, the BOVF Shares, and the CGEF Shares, except to the extent of their respective pecuniary interests.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

1. Great Point Partners, LLC

(a) Amount beneficially owned: 8,559,000 

(b) Percent of class: 9.99%1 

(c) Number of shares as to which the person has:

(i) Sole power to vote or direct the vote: 0

(ii) Shared power to vote or direct the vote: 8,559,000

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of: 8,559,000

 

2. Dr. Jeffrey R. Jay, M.D.

(a) Amount beneficially owned: 8,559,000 

(b) Percent of class: 9.99%1 

(c) Number of shares as to which the person has:

(i) Sole power to vote or direct the vote: 0

(ii) Shared power to vote or direct the vote: 8,559,000

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of: 8,559,000

 

3. Mr. Ortav Yehudai

(a) Amount beneficially owned: 8,559,000 

(b) Percent of class: 9.99%1 

(c) Number of shares as to which the person has:

(i) Sole power to vote or direct the vote: 0

(ii) Shared power to vote or direct the vote: 8,559,000

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of: 8,559,000

 

1 Based on a total of 85,681,212 shares outstanding as reported by the Issuer in its Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on July 5, 2024.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

See Item 4.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not Applicable.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group 

Not Applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 
CUSIP No. 90466Y103
 SCHEDULE 13G
Page 8 of 9 Pages

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: July 18, 2024

 

 

 

 

Great Point Partners, LLC

       
  By:  /s/ Dr. Jeffrey R. Jay, M.D.
    Dr. Jeffrey R. Jay, M.D., as Senior Managing Member
       
 

Dr. Jeffrey R. Jay, M.D.

       
  By:  /s/ Dr. Jeffrey R. Jay, M.D.
    Dr. Jeffrey R. Jay, M.D.
       
 

Mr. Ortav Yehudai

       
  By:  /s/ Mr. Ortav Yehudai
    Mr. Ortav Yehudai
       

 

 
CUSIP No. 90466Y103
 SCHEDULE 13G
Page 9 of 9 Pages

Exhibit A

 

JOINT FILING STATEMENT

 

PURSUANT TO RULE 13d-1(k)

 

The undersigned hereby agree as follows:

 

(i) Each of them is individually eligible to use the SCHEDULE 13G to which this Exhibit is attached, and such SCHEDULE 13G is filed on behalf of each of them; and

 

(ii) Each of them is responsible for the timely filing of such SCHEDULE 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

 

Dated: July 18, 2024

 

 

Great Point Partners, LLC

       
  By:  /s/ Dr. Jeffrey R. Jay, M.D.
    Dr. Jeffrey R. Jay, M.D., as Senior Managing Member
       
 

Dr. Jeffrey R. Jay, M.D.

       
  By:  /s/ Dr. Jeffrey R. Jay, M.D.
    Dr. Jeffrey R. Jay, M.D.
       
 

Mr. Ortav Yehudai

       
  By:  /s/ Mr. Ortav Yehudai
    Mr. Ortav Yehudai